Conference Abstract | Volume 9 (ConfPro8): Abstract 28 | Published: 06 Oct 2026
Philip Piyim Oduro1,&, Fred Newton Binka1, Verna Vanderpuye2, Margaret Kweku1, Joel Yarney2,3, Frank Baiden1
1Fred N. Binka School of Public Health, University of Health and Allied Sciences, Ho, Ghana; 2National Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle-Bu Teaching Hospital, Accra, Ghana; 3School of Medicine, University of Cape Coast, Cape Coast, Ghana
&Corresponding author: Philip Piyim Oduro, Fred N. Binka School of Public Health, University of Health and Allied Sciences, Ho, Ghana, Email: odurophilip2585@gmail.com, ORCID: https://orcid.org/0009-0006-5167-6539
Received: 11 Mar 2026, Accepted: 29 Aug 2026, Published: 06 Oct 2026
Domain: Cancer Epidemiology
Keywords: Prostate cancer, survival outcomes, treatment modalities, biochemical failure, Korle-Bu Teaching Hospital
©Philip Piyim Oduroet al. Journal of Interventional Epidemiology and Public Health (ISSN: 2664-2824). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cite this article: Philip Piyim Oduro et al., Survival outcomes and biochemical failure among prostate cancer patients treated with varied modalities at the Oncology and Urology Units of Korle-Bu Teaching Hospital, Ghana, 2010–2020. Journal of Interventional Epidemiology and Public Health. 2026;9(ConfPro8):28. https://doi.org/10.37432/JIEPH-CONFPRO8-0028
Prostate cancer remains a major public health concern in Ghana, with limited evidence on comparative survival outcomes across treatment modalities. This study evaluated survival outcomes and biochemical failure rates among prostate cancer patients treated with varied modalities at Korle-Bu Teaching Hospital (KBTH), Ghana.
A retrospective cohort study was conducted using secondary data from 1,206 patients with histologically confirmed prostate adenocarcinoma treated at the Oncology and Urology Units of KBTH (2010–2020). Socio-demographic, clinical, and treatment-related variables were examined. Kaplan–Meier survival estimates and log-rank tests were used to compare survival distributions. Cox proportional hazards regression models were employed to identify factors influencing disease-free (DFS), progression-free (PFS), biochemical failure-free (BFFS), and overall survival (OS). Multinomial logistic regression assessed determinants of treatment selection.
Combined radiotherapy and hormonal therapy achieved the highest 10-year OS (87.0%), followed by radiotherapy alone (84.1%), while hormonal therapy alone had the lowest (62.7%). Triple-modality therapy (radiotherapy + hormonal + brachytherapy) yielded the longest median OS (86.0 months). All survival outcomes showed significant differences across modalities (log-rank p < 0.05). Cox regression identified age, Gleason score 8–10 (HR = 1.8), PSA >50 ng/mL (HR = 2.0), advanced tumour stage T3b–T4 (HR = 1.8), hypertension (HR = 2.4), and diabetes (HR = 1.4) as significant adverse predictors. Triple-modality therapy reduced mortality hazard by 40% (HR = 0.6).
Menu